secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-119013
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte prices $15M registered direct offering of common stock and warrants at $5.34/unit
--------------------------------------------------------------------------------

- Pricing of 2,808,988 shares and warrants to purchase up to 2,808,988 shares at $5.34 per unit on Nov 14, 2024.
- Gross proceeds of approximately $15M before expenses; closing expected on or about Nov 15, 2024.
- Warrants split: 1,404,494 expire in 180 days; 1,404,494 expire in four and one-half years, both at $5.34 exercise.
- Company agrees to no further equity issuance or variable rate transactions until FDA approval for extremity vascular trauma or 30 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465924119013/0001104659-24-119013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465924119013/tm2428460d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-119013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer